Dr.BariatricHTX said:

I want to add the drug interaction perspective on the pharmacology.

This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.

Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

roxy_nash said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

I read this differently from roxy_nash, on substance rather than tone. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

One concrete data point for the thread. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Thread quality here is what the rules are for. Keep it up.